An industry group survey of generic drugs found that as of the end of August, 29% of the drugs surveyed were out of supply.
The group says that it has not improved since then and needs a mechanism to grasp the supply status of medicines.
Regarding generic drugs, problems such as the fact that they were manufactured by multiple manufacturers such as "Nichi-Iko" and "Kobayashi Kako" in a process not approved by the government were found, and supply was suspended or shipped in a wide range due to improvements in the manufacturing process. Adjustments are continuing.
At the request of the Ministry of Health, Labor and Welfare, the Japan Pharmaceutical Association conducted a questionnaire survey of pharmaceutical companies and others regarding the situation as of the end of August, and recently announced the results.
According to this, out of 9823 generic drugs from 218 companies that responded, supply was stagnant for 2890 items, which is 29.4%.
Specifically,
▽ "out of stock / suspension of shipment" was 7% for 686 items, and
▽ "shipment adjustment" was 22.4% for 2204 items.
Furthermore, due to the concentration of orders for generic drugs with the same ingredients, 4.4% of the 4665 items surveyed for generic drugs were out of stock or had shipment adjustments.
Naokazu Tsuchiya, chairman of the Japan Pharmaceutical Association, said, "The supply has been suspended for companies with a large market share since September, and it cannot be said that the situation has improved. A database of drugs that can quickly grasp the supply status. Is required to be created. "